MedTrace Logo

PD1 Integrated Anti-PSMA CART in Treating Patients With Castrate-Resistant Prostate Cancer

NCT04768608 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2023-07-17

No results posted yet for this study

Summary

PD1-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer

Conditions

  • Castrate-Resistant Prostate Cancer

Interventions

DRUG

PD1-PSMA-CART cells

PD1-PSMA-CART cells will be given IV at split doses

Sponsors & Collaborators

  • Bioray Laboratories

    collaborator INDUSTRY

  • Zhejiang University

    lead OTHER

Principal Investigators

  • Weijia Fang, MD · The First Affiliated Hospital, Zhejiang University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-23
Primary Completion
2022-06-30
Completion
2023-05-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04768608 on ClinicalTrials.gov